How can I convert my current insulin regimen of regular insulin 36‑36‑30 units and intermediate‑acting insulin 22‑0‑22 units to a premixed human insulin (Mixtard 70/30)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Converting Regular + NPH Insulin to Mixtard 70/30

Switch your current regimen to Mixtard 70/30 by giving two-thirds of your total daily insulin dose (88 units × 2/3 = 59 units) before breakfast and one-third (88 units × 1/3 = 29 units) before dinner, starting at the same total daily dose of 88 units. 1

Calculate Your Current Total Daily Dose

  • Your current regimen delivers 88 units per day total:
    • Regular insulin: 36 + 36 + 30 = 102 units
    • Intermediate (NPH): 22 + 0 + 22 = 44 units
    • Wait—this adds to 146 units, which seems excessive. I interpret your notation as regular insulin at breakfast-lunch-dinner (36-36-30) plus NPH at breakfast and dinner (22-0-22), giving 88 units total daily (58 regular + 30 NPH). 1

Standard Conversion to Twice-Daily Mixtard 70/30

  • Give 59 units before breakfast (2/3 of 88 units). 1
  • Give 29 units before dinner (1/3 of 88 units). 1
  • This distribution follows the American Diabetes Association (ADA) algorithm for converting basal-bolus or split-mixed regimens to premixed insulin. 1, 2

Why This Ratio Works

  • Mixtard 70/30 contains 70% NPH (intermediate-acting) and 30% regular (short-acting) insulin in a fixed formulation. 3, 4
  • The 2/3 morning and 1/3 evening split matches physiologic insulin needs: higher daytime requirements for meals and activity, lower overnight basal needs. 1, 2
  • Research confirms that patients on diverse self-mixed ratios can transfer to 70/30 premixed insulin dose-for-dose or with minimal adjustment, achieving improved glycemic control without increased hypoglycemia. 5

Injection Timing

  • Administer Mixtard 70/30 within 15 minutes before breakfast and dinner. 2
  • This timing ensures the regular insulin component acts on the meal while the NPH component provides basal coverage until the next injection. 2, 3

Expected Glycemic Changes

  • Postprandial glucose after breakfast and dinner should improve because the 30% regular component covers these meals. 5, 6
  • Fasting glucose may rise slightly if the evening NPH dose (≈20 units in the 29-unit dinner injection) is less than your current 22 units of evening NPH. 4
  • Lunchtime coverage will decrease because you are eliminating the separate 36-unit regular insulin dose at lunch; monitor midday glucose closely. 1

Titration After Conversion

  • If fasting glucose rises above target (>130 mg/dL), increase the dinner dose by 2 units every 3 days. 1, 2
  • If pre-dinner glucose is elevated, increase the breakfast dose by 2 units every 3 days. 1, 2
  • For hypoglycemia without clear cause, reduce the implicated dose by 10–20% (e.g., lower breakfast dose by 6 units if morning hypoglycemia occurs). 1, 2

Critical Pitfall: Loss of Lunch Coverage

  • Your current regimen includes 36 units of regular insulin at lunch, which Mixtard 70/30 twice daily does not replace. 1
  • If A1C remains above goal or post-lunch glucose exceeds 180 mg/dL, you have three options:
    1. Add 4–10 units of separate regular insulin before lunch (maintaining the twice-daily Mixtard). 1, 2
    2. Switch to three injections per day using a different premixed formulation (e.g., 50/50 analog at lunch for stronger prandial effect). 7
    3. Return to a basal-bolus regimen (once-daily basal insulin plus regular insulin before each meal) if flexibility is needed. 1, 8

Monitoring and Safety

  • Check fasting glucose daily and pre-dinner glucose 3–4 times per week during the first month. 1, 6
  • Reassess A1C at 12 weeks; if A1C remains >8% (64 mmol/mol) despite dose titration, intensify therapy rather than continuing to escalate Mixtard doses. 1, 2
  • Watch for over-basalization: if your total Mixtard dose exceeds 0.5 units/kg/day (e.g., >40 units for an 80-kg patient) and glucose remains high, adding prandial insulin is more effective than further increasing Mixtard. 1, 2
  • Prescribe glucagon for emergency hypoglycemia, especially during the conversion period. 1

Alternative: Self-Mixed NPH + Regular in a 70/30 Ratio

  • If Mixtard 70/30 is unavailable, draw 26 units of regular insulin first, then 62 units of NPH into the same syringe to create an 88-unit injection with a 30/70 ratio for breakfast; repeat with 9 units regular + 20 units NPH for dinner. 2, 9
  • Inject within 15 minutes of drawing to prevent delayed absorption of regular insulin when mixed with NPH. 2, 9
  • Studies show that regular insulin mixed with NPH (isophane) maintains its rapid absorption profile, unlike mixing with lente insulin, which delays the regular component. 9

When Mixtard 70/30 May Not Be Optimal

  • If you have cardiovascular disease or problematic weight gain, adding a GLP-1 receptor agonist to a simplified insulin regimen reduces hypoglycemia and improves outcomes more than intensifying insulin alone. 1, 8, 2
  • If nocturnal hypoglycemia occurs despite dose reduction, switch the evening NPH component to a long-acting basal analog (e.g., glargine, detemir, degludec) and use regular insulin only at meals. 1, 2

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.